The board of directors of NeuPath Health Inc. comprised individuals with experience that is directly relevant for the implementation of the accelerated growth strategy. With the need and fit identified, Dianne Carmichael has accepted the newly created role of Executive Chair and will be supported by Joseph Walewicz in the new role of Chief Business Officer. Together, the Executive Chair and the Chief Business Officer will work with the entire NeuPath team to optimize the existing continuum of comprehensive care across the entire organization, while evaluating new business opportunities and potential business transactions to grow and enhance patient care and business performance.

Grant Connelly has agreed to step down as the Chief Executive Officer and assist Dianne and Joe transition into their new roles. Dianne and Joe will remain on the Board of Directors of NeuPath, but Dianne will step aside from the Compensation, Nomination and Corporate Governance Committee ("CNGC Committee") and Joe will step aside from the Audit Committee. The new CNGC Committee members will be Sacha Cucuz, Dan Legault and Dan Chicoine.

Dan Chicoine will continue to chair the Audit Committee, with Dan Legault joined by new member Sacha Cucuz. Ms. Carmichael has over 30 years of diverse executive management and board of director experience spanning from start-up and growth companies to Fortune 500 multinationals. Dianne was Chairman & CEO of a publicly traded investment firm before shifting to healthcare to make a difference in the lives of those touched by profound illness.

As President of Best Doctors Inc., she helped create a remote second opinion platform that connected patients with the top 2% of medical experts worldwide and which covers over 40 million international patients. Most recently she was President of Payer & Care Markets and Head of Corporate Strategy and M&A at McKesson, a Fortune 5 healthcare company. While at McKesson.

Prior to McKesson, Dianne was President, UHN Solutions at UHN, Canada's leading group of research hospitals, and Managing Director, MaRS Health Ventures and Innovation. Furthermore, Dianne formerly served as the Chief Advisor for the HealthTech division of the Council of Canadian Innovators, founded by Jim Balsillie, where they bring the voice of Canadian tech CEOs to government and policy makers. Ms. Carmichael continues to make a difference for patients by helping health-tech companies bring high impact innovations to scale globally through her company, Carmichael Worldwide Inc. Dianne has served on numerous healthcare boards and government think tank committees, including Holland Bloorview Kids Rehab Hospital, PatientsCanada, CAPCH, Centre for Regenerative Medicine, Mt.

Sinai's Personalized Medicine Institute, Women's Brain Health Initiative & World Health Innovation Network (W.I.N.). She was awarded Canada's Most Powerful Women by WXN, Canadian Women Transforming Health Care and University of Waterloo Alumni of the Year. She holds a B.A. from the University of Waterloo and holds the ICD.D Board of Directors designation from the Institute of Corporate Directors/Rotman.

Mr. Joseph (Joe) Walewicz was Executive Vice President, Business and Corporate Development of Clementia Pharmaceuticals, a NASDAQ-listed company, from 2017 to 2019, prior to Clementia's acquisition by Ipsen Pharmaceuticals for $1 billion in April of 2019. Mr. Walewicz has spent 25 years in biopharma, serving on the board and at the executive level of multiple publicly traded healthcare companies including Clementia Pharmaceuticals, MethylGene Inc., Warnex Inc. and Paladin Labs, and as a top ranked equities analyst for major North American banks including CIBC, BMO and Lehman Brothers where he covered publicly traded North American biotechnology, pharmaceuticals, medtech and healthcare services companies. Mr. Walewicz holds a Master of Business Administration, Finance from McGill University, as well as a Bachelor of Science, Biochemistry, and a Bachelor of Arts, Economics from Queen's University.

Mr. Walewicz is also a CFA (Chartered Financial Analyst) charterholder.